Product Images Leflunomide
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Leflunomide NDC 46708-436 by Alembic Pharmaceuticals Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a medication label for Lefunomide tablets containing 10mg of the medication. Dosage instructions and storage conditions are mentioned. The packaging has a child-resistant cap and a tamper-evident seal. The medication is manufactured by Alembic Pharmaceuticals in Gujarat, India. The label includes the batch number, expiry date, and a National Drug Code (NDC) for the tablets. The medication is available only with a prescription.*
Each film-coated tablet contains Lefunomide USP 20mg. Dosage and Administration instructions are available in the package insert. Store the tablets at a temperature between 25°C and 30°C (77°F to 86°F) and protect them from light. This package has a tamper-evident cap and is child-resistant. The tablets are manufactured by Alembic Pharmaceutical Limited in India. The product is available in packages of 30 tablets and requires a prescription. The lot number and expiration date are not available.*
This is a table showing the percentage of ACR 20 responders at different endpoints in three trials. The trials are identified by Trial 1, Trial 2, and Trial 3, and the time periods measured are 6 months and 12 months. The treatments being tested are Methotrexate and placebo. No further information is available.*
This appears to be a chart or graph showing the percentage of ACR (American College of Rheumatology) responders over time in Trial 1. The data is likely presented in a visual format with a Y-axis representing the percentage of responders and an X-axis representing time. The specific data points and trends cannot be determined without the graphic itself.*
The text describes a change in functional ability measure over a period of 12 months, including improvement. The measure is likely related to the HAQ Disability Index, although it is unclear what the LMPLsPL represents. The rest of the text is not understandable.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.